Shares of Audentes Therapeutics Inc (NASDAQ:BOLD) have received a consensus rating of “Buy” from the eighteen research firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and fourteen have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $41.53.

Several brokerages have issued reports on BOLD. BidaskClub raised shares of Xilinx from a “hold” rating to a “buy” rating in a research note on Saturday, June 29th. Wedbush reissued a “hold” rating and issued a $2.00 price objective on shares of Regulus Therapeutics in a research note on Tuesday, April 9th. BMO Capital Markets cut shares of Capital Power from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 8th. HC Wainwright set a $31.00 price objective on shares of Kura Oncology and gave the company a “buy” rating in a research note on Wednesday, May 8th. Finally, Piper Jaffray Companies set a $20.00 price target on shares of Immunomedics and gave the stock a “buy” rating in a research note on Monday, April 8th.

In other news, Director Louis G. Lange sold 21,000 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $37.79, for a total transaction of $793,590.00. Following the transaction, the director now directly owns 290,001 shares of the company’s stock, valued at approximately $10,959,137.79. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Suyash Prasad sold 10,000 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $36.98, for a total transaction of $369,800.00. Following the transaction, the vice president now directly owns 28,236 shares in the company, valued at $1,044,167.28. The disclosure for this sale can be found here. Corporate insiders own 5.30% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. NumerixS Investment Technologies Inc boosted its position in shares of Audentes Therapeutics by 1,200.0% in the 4th quarter. NumerixS Investment Technologies Inc now owns 1,300 shares of the biotechnology company’s stock worth $27,000 after buying an additional 1,200 shares in the last quarter. Amundi Pioneer Asset Management Inc. purchased a new stake in shares of Audentes Therapeutics in the 4th quarter worth about $92,000. Great West Life Assurance Co. Can boosted its position in shares of Audentes Therapeutics by 96.0% in the 4th quarter. Great West Life Assurance Co. Can now owns 4,726 shares of the biotechnology company’s stock worth $97,000 after buying an additional 2,315 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Audentes Therapeutics by 34.5% in the 4th quarter. Legal & General Group Plc now owns 6,632 shares of the biotechnology company’s stock worth $141,000 after buying an additional 1,700 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. purchased a new stake in shares of Audentes Therapeutics in the 1st quarter worth about $264,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

BOLD traded down $0.18 during trading on Monday, hitting $37.90. The stock had a trading volume of 304,044 shares, compared to its average volume of 471,933. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -11.15 and a beta of 1.70. The business has a 50-day moving average of $37.42. Audentes Therapeutics has a twelve month low of $17.95 and a twelve month high of $42.69.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.23). During the same quarter in the prior year, the business earned ($0.74) EPS. Sell-side analysts forecast that Audentes Therapeutics will post -4.43 EPS for the current year.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Article: Hold Rating

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.